Diurnal Group PLC
LSE:DNL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Diurnal Group PLC
Capital Expenditures
Diurnal Group PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Diurnal Group PLC
LSE:DNL
|
Capital Expenditures
-£118k
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Capital Expenditures
-$2.4m
|
CAGR 3-Years
50%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Capital Expenditures
-£4.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Capital Expenditures
-£18.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Capital Expenditures
-£4.8m
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Diurnal Group PLC
Glance View
Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. The firm is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. Its research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The firm's product, Alkindi, is a hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI). Alkindi is an oral, immediate-release pediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. Its pipeline includes Chronocort, DITEST, T3 modified release and Oligonucleotide (siRNA). Chronocort is a modified-release preparation of hydrocortisone that is specifically designed to mimic the circadian rhythm of cortisol.
See Also
What is Diurnal Group PLC's Capital Expenditures?
Capital Expenditures
-118k
GBP
Based on the financial report for Jun 30, 2022, Diurnal Group PLC's Capital Expenditures amounts to -118k GBP.
What is Diurnal Group PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-43%
Over the last year, the Capital Expenditures growth was 28%. The average annual Capital Expenditures growth rates for Diurnal Group PLC have been -24% over the past three years , -43% over the past five years .
